Cite
HARVARD Citation
Urbonas, V. et al. (2019). Paclitaxel with or without trametinib or pazopanib in advanced wild-type BRAF melanoma (PACMEL): a multicentre, open-label, randomised, controlled phase II trial. Annals of oncology. pp. 317-324. [Online].